Interleukin-17: from clone to clinic
24 min
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Improving on "Natural" Rodent Antibodies
-
26 min
1. The immunogenicity problem in antibody therapy- Prof. Herman Waldmann
-
32 min
2. Antibodies by protein engineering- Prof. Sir Gregory Winter
-
60 min
3. The generation of diversity in antibody genes- Prof. Michael Neuberger
-
51 min
4. Innate immunity to retroelements by human AID/APOBEC3 proteins- Prof. Reuben Harris
-
36 min
5. Fc receptors and antibody effector functions- Dr. Mike Clark
-
57 min
6. Antibody engineering of Fc effector functions- Dr. Mike Clark
-
35 min
7. Antibody engineering: beginnings to bispecifics and beyond- Dr. Ian Wilkinson
- Antibodies in Cancer Therapy
-
41 min
8. Monoclonal antibodies and the ErbB system in human cancer- Prof. Mark Greene
-
71 min
9. Checkpoint blockade in cancer immunotherapy- Prof. James Allison
-
45 min
10. Monoclonal antibodies in haemato-oncology- Prof. Mark Cragg
- Diagnostic Antibodies
-
46 min
11. Monitoring therapy with antibodies- Dr. Geoffrey Hale
- Cell Surface Glycoproteins on Cells of the Immune System
-
38 min
12. Cell surface glycoproteins on cells of the immune system- Prof. Neil Barclay
- Antibodies as Immunosuppressants
-
29 min
13. Monoclonal antibodies to induce therapeutic immunological tolerance- Prof. Herman Waldmann
-
29 min
14. Antibodies to control or prevent type 1 diabetes- Dr. Robert Hilbrands
-
48 min
15. Antibody therapy of multiple sclerosis- Dr. Alasdair Coles
- Prof. Alastair Compston
-
42 min
16. Monoclonal antibodies in the management of rheumatoid arthritis- Prof. John Isaacs
-
40 min
-
30 min
- Archived Lectures *These may not cover the latest advances in the field
-
26 min
19. Alemtuzumab (Campath-1H) in therapy of CLL- Prof. Kanti Rai
-
71 min
20. VEGF inhibitors for anti-angiogenic therapy- Prof. Kari Alitalo
- Dr. Bronislaw Pytowski
-
26 min
21. Human antibodies produced in mice- Dr. Marianne Bruggemann
-
52 min
22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man- Prof. Christian Larsen
-
55 min
23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity- Prof. Thomas Tedder
-
45 min
24. Anti-IL-2 receptor antibodies as models for cancer therapy- Prof. Thomas Waldmann
-
58 min
25. Anti TNF therapy in rheumatoid arthritis- Prof. Marc Feldmann
-
36 min
26. Novel immunotherapeutic proteins: immunoligand- Prof. Terry Strom
-
21 min
27. Diagnostic immunohistopathology- Prof. David Mason
-
56 min
28. Antibodies in the control of type I diabetes- Prof. Lucienne Chatenoud
-
43 min
29. The challenge of targeting toxins to tumors- Prof. Ben Seon
-
38 min
30. Antibody depletion therapy in transplantation: implications for tolerance- Prof. Laurence Turka
-
36 min
31. Antibodies as anti-virals- Prof. Dennis Burton
Printable Handouts
Navigable Slide Index
- Introduction
- Unique features of alloreactivity
- Estimating frequency of alloreactive T cells in vivo
- Alloreactive precursor frequency
- Tolerance approaches
- T cells costimulatory pathways
- Blockade induces transplant tolerance
- Distinct effects of CD28 costimulation
- Apoptotic T cells induce transplantation tolerance
- Calcineurin inhibition antagonizes blockade
- Antagonism of blockade and calcineurin inhibitors
- Reduction in T cells number facilitates tolerance
- How to delete alloreactive cells?
- Homeostatic proliferation
- Homeostatic proliferation: a barrier to tolerance
- Homeostatic proliferation and memory generation
- Memory-like functional responses
- Memory T cells abrogate graft prolongation
- Cardiac allograft rejection in scid mice
- Scid mice resist tolerance induction
- Homeostatic proliferation of B6 T cells
- T cells depletion leads to proliferation (1)
- T cells depletion leads to proliferation (2)
- Incomplete T cells depletion affects tolerance
- Do memory cells develop due to failure to tolerize?
- BrdU incorporation in transferred B6 T cells
- Cardiac allograft rejection
- Failure to maintain suppressor cells
- % of CD4+CD25+ after homeostatic proliferation
- T cells from reconstituted scid mice
- Reconstituting normal mice made T-cell deficient
- Failure to tolerize after homeostatic proliferation
- Reduction in clonal mass facilitates tolerance
- Heterologous immunity: a barrier to tolerance (1)
- Heterologous immunity: a barrier to tolerance (2)
- Memory cells in partial depletion, lymphopenia
- Various types of cells in the aftermath of depletion
- Differential depletion
- Sparing of memory T cells after depletion
- Differential proliferation
- Testing differential proliferation
- Proliferation of memory T cells after depletion (1)
- Proliferation of memory T cells after depletion (2)
- Depletion doesn't alter the proportion of CD4 cells
- CD4+CD25+ Tregs versus non-regulatory T cells
- Prevention of rejection of homeostatic proliferation
- Restoring tolerance induction by Tregs
- Restoring tolerance induction by anti-CD4/CD8
- Anti-CD4/CD8 block homeostatic proliferation
- Why is transplant tolerance hard to achieve?
- Acknowledgements
Topics Covered
- Overview of alloreactivity
- Tolerance approaches
- Co-stimulatory blockade
- Requirement for cell depletion
- Homeostatic proliferation overview
- Homeostatic proliferation generates memory cells and blocks tolerance induction
- Depletion spares memory cells
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Turka, L. (2007, October 1). Antibody depletion therapy in transplantation: implications for tolerance [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/NEPF3205.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Laurence Turka has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Antibody depletion therapy in transplantation: implications for tolerance
A selection of talks on Immunology & Inflammation
Hide